))
Unveiling the Latest Advancements in CKD-Associated Pruritus Care
Manage episode 456468875 series 3381434
A tartalmat a ReachMD biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a ReachMD vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
CME credits: 0.25
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/unveiling-the-latest-advancements-in-ckd-associated-pruritus-care/26636/
Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA. =
…
continue reading
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/unveiling-the-latest-advancements-in-ckd-associated-pruritus-care/26636/
Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA. =
461 epizódok
Megosztás
